Research for other indications is ongoing. In the first trial of microRNA inhibition to treat heart failure, a novel agent ...
An 8-month low-calorie diet plus behavioral support helped older adults with overweight or obesity and persistent atrial ...
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Trial of HTX-001, an Investigational Cellular Reprogramming Therapy ...
The endoplasmic reticulum (ER) regulates protein folding and maintains proteostasis in cells- a process essential to maintaining cellular health. However, researchers at UAB have found that chronic ...
HeartLung Corporation announced the publication of a new study in the American Journal of Preventive Cardiology titled “Comparing Incidence of Heart Failure in Individuals with Enlarged Cardiac ...
Following an acute heart attack, pathological remodeling processes occur in the heart. One consequence is so-called left ...
Cardiac physiologic pacing, also known as cardiac resynchronization therapy, is indicated in patients with heart failure, reduced left ventricular ejection fraction (LVEF) of 50% or less, and either a ...
Researchers at the Mount Sinai Kravis Children's Heart Center led a multicenter effort to develop and validate an artificial intelligence (AI) tool that can analyze a standard electrocardiogram (ECG) ...
First RNA trial: HF-REVERT is the first randomized trial to test microRNA inhibition in heart failure after a heart attack. Mixed efficacy results: CDR132L did not significantly improve the main heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results